27th Feb 2014 14:03
LONDON (Alliance News) - Silence Therapeutics PLC said Thursday that it had made progress in both its pre clinic and clinical programmes during 2013, in a year end trading update.
Silence said that patient enrollment for its Phase IIa trial in pancreatic cancer is progressing, and it expects to begin its head and neck oncology Phase Ib trial in the second-half of 2014.
Silence is on track to file an investigational new drug application for its pulmonary disease treatment Atu111 in the second half of 2014 or first half of 2015.
The biotechnology company had a cash position as at February 2014 of GBP19.3 million.
Shares in Silence Therapeutics PLC were trading up 0.2% at 375.80 pence Thursday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
SLN.L